![](https://investorshub.advfn.com/uicon/315468.png?cb=1473363790)
Tuesday, May 15, 2018 3:52:49 PM
How in the hell is someone with a rare occurrence of when multiple myeloma metastasizes to the skin is going to become involved in a efficacy study for a topical cream to treat psoriasis?
This arguments is weak at best.
First do you understand how rare multiple Myeloma effects fewer than 200,000 people in the U.S.
So in the US that is 0.06% of the population.
The population of Israel is 8.5 million.
That is 5100 people in Israel that have Multiple Myeloma - so the chances that the efficacy study has the one of the 5100 (and mush less than that with MM that has metastasized to the skin) is so small that it isn't possible to believe the OWCP nonsense for the delay in the efficacy report.
IG
"Are you gonna pull those pistols or whistle Dixie?"
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM